Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021

Sunitinib malate is a small multi‐targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor (PDGFR) and stem cell factor receptor (KIT), which are highly expressed by some high‐grade brain tumors. We conducted a phas...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Wetmore, Cynthia, Daryani, Vinay M., Billups, Catherine A., Boyett, James M., Leary, Sarah, Tanos, Rachel, Goldsmith, Kelly C., Stewart, Clinton F., Blaney, Susan M., Gajjar, Amar
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2016
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944867/
https://ncbi.nlm.nih.gov/pubmed/27109549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.713
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia